English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

73 3 Antithrombotic Trialists’ Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86. 4 Algra A, van Gijn J, Koudstaal PJ: Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone? J Neurol Neurosurg Psychiatry 1999; 66: 557–559. 5 European Stroke Prevention Study 2: efficacy and safety data. J Neurol Sci 1997; 151(suppl):S1–S77. 6 Dresse A, Chevolet C, Delapierre D, Masset H, Weisenberger H, Bozler G, Heinzel G: Pharmacokinetics of oral dipyridamole (Persantine) and its effect on platelet adenosine uptake in man. Eur J Clin Pharmacol 1982; 23: 229–234. 7 Derendorf H, Vander Maelen CP, Brickl RS, MacGregor TR, Eisert W: Dipyridamole bioavailability in subjects with reduced gastric acidity. J Clin Pharmacol 2005; 45: 845–850.

Reply to the Letter by Derendorf: Clinical Trials and Dipyridamole Formulation Selection